Literature DB >> 21804091

Uremia alters HDL composition and function.

Michael Holzer1, Ruth Birner-Gruenberger, Tatjana Stojakovic, Dalia El-Gamal, Veronika Binder, Christian Wadsack, Akos Heinemann, Gunther Marsche.   

Abstract

Functional impairment of HDL may contribute to the excess cardiovascular mortality experienced by patients with renal disease, but the effect of advanced renal disease on the composition and function of HDL is not well understood. Here, we used mass spectrometry and biochemical analyses to study alterations in the proteome and lipid composition of HDL isolated from patients on maintenance hemodialysis. We identified a significant increase in the amount of acute phase protein serum amyloid A1, albumin, lipoprotein-associated phospholipase A2, and apoC-III composing uremic HDL. Furthermore, uremic HDL contained reduced phospholipid and increased triglyceride and lysophospholipid. With regard to function, these changes impaired the ability of uremic HDL to promote cholesterol efflux from macrophages. In summary, the altered composition of HDL in renal disease seems to inhibit its cardioprotective properties. Assessing HDL composition and function in renal disease may help identify patients at increased risk for cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21804091      PMCID: PMC3171935          DOI: 10.1681/ASN.2010111144

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  46 in total

1.  Apolipoprotein CIII and atherosclerosis: beyond effects on lipid metabolism.

Authors:  Alex Bobik
Journal:  Circulation       Date:  2008-08-12       Impact factor: 29.690

2.  Proteomic analysis of high-density lipoprotein.

Authors:  Farhad Rezaee; Bruno Casetta; J Han M Levels; Dave Speijer; Joost C M Meijers
Journal:  Proteomics       Date:  2006-01       Impact factor: 3.984

3.  Investigation of an albumin-enriched fraction of human serum and its albuminome.

Authors:  Rebekah L Gundry; Qin Fu; Christine A Jelinek; Jennifer E Van Eyk; Robert J Cotter
Journal:  Proteomics Clin Appl       Date:  2007-01-01       Impact factor: 3.494

4.  Dissociable and nondissociable forms of platelet-activating factor acetylhydrolase in human plasma LDL: implications for LDL oxidative susceptibility.

Authors:  M R McCall; M La Belle; T M Forte; R M Krauss; Y Takanami; D L Tribble
Journal:  Biochim Biophys Acta       Date:  1999-01-29

5.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

6.  Role of serum amyloid A during metabolism of acute-phase HDL by macrophages.

Authors:  A Artl; G Marsche; S Lestavel; W Sattler; E Malle
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-03       Impact factor: 8.311

Review 7.  Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease.

Authors:  P Stenvinkel
Journal:  J Intern Med       Date:  2010-11       Impact factor: 8.989

8.  2-chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein-associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis.

Authors:  Gunther Marsche; Regine Heller; Günter Fauler; Alenka Kovacevic; Alexander Nuszkowski; Wolfgang Graier; Wolfgang Sattler; Ernst Malle
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-10-28       Impact factor: 8.311

9.  Specific phospholipid association with apolipoprotein A-I stimulates cholesterol efflux from human fibroblasts. Studies with reconstituted sonicated lipoproteins.

Authors:  Y Zhao; D L Sparks; Y L Marcel
Journal:  J Biol Chem       Date:  1996-10-11       Impact factor: 5.157

10.  Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux.

Authors:  Sandhya Sankaranarayanan; John F Oram; Bela F Asztalos; Ashley M Vaughan; Sissel Lund-Katz; Maria Pia Adorni; Michael C Phillips; George H Rothblat
Journal:  J Lipid Res       Date:  2008-09-30       Impact factor: 5.922

View more
  115 in total

Review 1.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 2.  Chronic kidney disease induced dysfunction of high density lipoprotein.

Authors:  Suguru Yamamoto; Valentina Kon
Journal:  Clin Exp Nephrol       Date:  2013-09-10       Impact factor: 2.801

3.  Biochemical and functional characterization of charge-defined subfractions of high-density lipoprotein from normal adults.

Authors:  Ju-Yi Hsieh; Chiz-Tzung Chang; Max T Huang; Chia-Ming Chang; Chia-Ying Chen; Ming-Yi Shen; Hsin-Yi Liao; Guei-Jane Wang; Chu-Huang Chen; Chao-Jung Chen; Chao-Yuh Yang
Journal:  Anal Chem       Date:  2013-11-13       Impact factor: 6.986

4.  Apoprotein B/Apoprotein A-1 Ratio and Mortality among Prevalent Dialysis Patients.

Authors:  Yuji Sato; Shouichi Fujimoto; Tatsunori Toida; Hideto Nakagawa; Yasuhiro Yamashita; Takashi Iwakiri; Akihiro Fukuda; Shuji Iwatsubo
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-15       Impact factor: 8.237

Review 5.  Hemodialysis-induced cardiovascular disease.

Authors:  Shadi Ahmadmehrabi; W H Wilson Tang
Journal:  Semin Dial       Date:  2018-04-06       Impact factor: 3.455

Review 6.  Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations.

Authors:  Heidi Noels; Michael Lehrke; Raymond Vanholder; Joachim Jankowski
Journal:  Nat Rev Nephrol       Date:  2021-05-10       Impact factor: 28.314

Review 7.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

Review 8.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

9.  Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients?

Authors:  Anna Gluba-Brzózka; Beata Franczyk; Maciej Banach; Magdalena Rysz-Górzyńska
Journal:  Int Urol Nephrol       Date:  2016-12-09       Impact factor: 2.370

Review 10.  Role of HDL dysfunction in end-stage renal disease: a double-edged sword.

Authors:  Hamid Moradi; Nosratola D Vaziri; Moti L Kashyap; Hamid M Said; Kamyar Kalantar-Zadeh
Journal:  J Ren Nutr       Date:  2013-05       Impact factor: 3.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.